Who Prioritizes Innovation? R&D Spending Compared for Ascendis Pharma A/S and Ionis Pharmaceuticals, Inc.

R&D Spending: Ascendis vs. Ionis - A Decade of Innovation

__timestampAscendis Pharma A/SIonis Pharmaceuticals, Inc.
Wednesday, January 1, 201419698000241751000
Thursday, January 1, 201540528000322292000
Friday, January 1, 201666022000344320000
Sunday, January 1, 201799589000374644000
Monday, January 1, 2018140281000414604000
Tuesday, January 1, 2019191621000466000000
Wednesday, January 1, 2020260904000535000000
Friday, January 1, 2021295867000643000000
Saturday, January 1, 2022379624000833000000
Sunday, January 1, 2023413454000899625000
Monday, January 1, 2024307004000901530000
Loading chart...

In pursuit of knowledge

Innovation in Pharmaceuticals: A Comparative Analysis

In the competitive world of pharmaceuticals, innovation is key to staying ahead. Ascendis Pharma A/S and Ionis Pharmaceuticals, Inc. have been at the forefront of this race, with their R&D spending reflecting their commitment to innovation. Over the past decade, Ionis Pharmaceuticals has consistently outspent Ascendis Pharma, with R&D expenses peaking at nearly 900 million USD in 2023, a staggering 270% increase from 2014. In contrast, Ascendis Pharma's R&D spending grew by over 2000% during the same period, reaching approximately 413 million USD in 2023. This rapid growth highlights Ascendis Pharma's aggressive push towards innovation. While Ionis maintains a higher absolute spend, Ascendis's growth trajectory suggests a strategic pivot towards research-driven development. As these companies continue to invest in R&D, the pharmaceutical landscape is set for exciting advancements.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025